A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital of Wenzhou Medical University
About this trial
The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:
The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
cTn>99th ULN or CK-MB>99th ULN
ST-segment elevation with a convex upward morphology
in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
cTn>99th ULN or CK-MB>99th ULN
Disqualifiers
Lactating or pregnant women
Patients with malignant neoplasms
Severe hepatic/renal dysfunction
Severe hematological disorders
Trial population
Patients who presented to Lishui Central Hospital (Fifth Affiliated Hospital of Wenzhou Medical University) due to cardiac discomfort or other related symptoms were consecutively enrolled in the present study.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
310 Participants
are grouped into 3 trial groupsGroup A: ACS
Group B: Control
Group C: CCS
Trial outcomes
Primary outcomes
1
circulating fibroblast growth factors (FGFs) levels
examining the circulating fibroblast growth factors levels in the peripheral venous blood of the participants
Time frame
within 24 hours of admission to the hospital2
circulating inflammatory cytokines levels
examining the circulating inflammatory cytokines levels in the peripheral venous blood of the participants
Time frame
within 24 hours of admission to the hospital3
circulating chemokines levels
examining the circulating chemokines levels in the peripheral venous blood of the participants
Time frame
within 24 hours of admission to the hospital4
circulating Cytochrome C level
examining the circulating cytochrome c levels in the peripheral venous blood of the participants
Time frame
within 24 hours of admission to the hospitaSecondary outcomes
1
the relationship between FGFs/inflammatory cytokines/chemokines and troponin I (TnI)
performed correlation analyses between the circulating levels of FGFs/inflammatory cytokines/chemokines and TnI
Time frame
within 24 hours of admission to the hospital2
the relationship between FGFs/inflammatory cytokines/chemokines and brain natriuretic peptide (BNP)
performed correlation analyses between the circulating levels of FGFs/inflammatory cytokines/chemokines and BNP
Time frame
within 24 hours of admission to the hospital3
the relationship between FGFs/inflammatory cytokines/chemokines and lactate dehydrogenase (LDH)
performed correlation analyses between the circulating levels of FGFs/inflammatory cytokines/chemokines and LDH
Time frame
within 24 hours of admission to the hospital4
the relationship between FGFs/inflammatory cytokines/chemokines and left ventricular ejection fraction (LVEF)
performed correlation analyses between the circulating levels of FGFs/inflammatory cytokines/chemokines and LVEF
Time frame
within 24 hours of admission to the hospitalSponsors and contacts
Click on the lead sponsor to view all of their trials.
Second Affiliated Hospital of Wenzhou Medical University
Lead sponsor
The Central Hospital of Lishui City
Collaborator
Source ClinicalTrials.gov